Clinical evaluation of cefmenoxime(sce-1365) in chronic respiratory tract infections

Keizo Matsumoto, Nobuo Maekawa, Fumio Nagahama, Kiyoshi Konno, Takao Takizawa, Yukio Nishimoto, Hitoshi Nagano, Sokichi Onodera, Eiichi Sakai, Nobuhiro Sasaki, Makoto Murao, Yutaka Ohsaki, Tsuguo Terai, Tatsunori Shimizu, Yohmei Hiraga, Kohki Kikuchi, Masaru Nakahashi, Shinya Yasuda, Masashi Tamura, Takashi ItohJun Komuro, Masato Hayashi, Tuneyasu Sawaguchi, Tamotsu Takishima, Kazuki Konishi, Kiyo Nishioka, Kohtaroh Oizumi, Akira Watanabe, Sriichi Aonuma, Izumi Hayashi, Atsushi Nagai, Hirovuki Kohayashi, Kohta Kohno, Kenzi Takamura, Mitsuko Takamura, Hideo Ikemoto, Kazuyoshi Watanabe, Junko Hibino, Hiroichi Tanimoto, Koichiro Nakata, Akio Tachibana, Naohiko Chonabayashi, Yoshitaka Nakamori, Keiichi Nakagawa, Katsuhito Itoh, Masaru Koyama, Hirosuke Nakazawa, Masami Ueda, Genichi Tanaka, Yasuyuki Yoshizawa, Takashi Nakazawa, Shigeru Nagaoka, Norio Kihara, Seiichi Nakamura, Michiyoshi Harasawa, Yoshinosuke Fukuchi, Kiyotaka Yano, Toshihiko Haga, Naohiro Nagayama, Kazuko Machida, Osamu Sekine, Yoshimaru Usuda, Nobuki Aoki, Kaoru Ohyama, Kuniyoshi Suzuki, Tatsuo Satake, Ikuo Yamakawa, Hiromichi Umeda, Susumu Suetsugu, Katsutaka Torigai, Michiyasu Nakanishi, Takuya Kurasawa, Makoto Muto, Nobuo Sakurai, Kenzo Shioda, Fumio Miki, Kknzi Takamatsu, Shigenori Nakazima, Hiroshi Takagi, Hisao Takahashi, Norio Ochi, Akio Ichinosawa, Takkhiro Tsuzimoto, Keniciii Shimizu, Rinzo Soejima, Yoshihi Futagi Io, Masavasu Kawanisiii, Michio Yamakido, Osamu Kurimura, Eiro Tsubura, Yoshihiro Takishita, Toshihiro Goto, Tsuneo Ishibashi, Masahiro Takamoto, Minoru Yoshida, Fumihiko Maeda, Hiroshi Kutsukake, Masataka Oyamada, Haruhiko Tokuomi, Masayuki Andou, Yasutsugu Fukuda, Katsumasa Tokunaga, Yasumasa Hiro, Hiroaki Naoe, Takenori Hiraoka, Kouhei Hara, Masao Nakatomi, Keizou Yamaguchi, Yoshiteru Shigeno, Tsuneo Tsutsumi, Takeshi Ishizaki, Tsuyoshi Nagatake, Tomoyuki Harada

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    Efficacy and safety of cefmenoxime (CMX, SCE-1365) and cefotiam (CTM) were compared by a randomized, double blind method. CMX as well as CTM were administered daily 2 gms, i. e. 2 times of 1 gm intravenous drip infusion, for consecutive 7 to 14 days. In total 162 cases, which consist of each 81 CMX and CTM allocated cases, were subjected to the analysis, and the following results were obtained. 1) In the distribution of patient-characteristics(background factor)between CMX and CTM allocated group, the statistical analysis showed there was no bias, which will virtually influence on the results. 2) Overall clinical efficacy rates of CMX and CTM were 77.0% and 60.3% respectively. CMX showed significantly higher clinical efficacy rate than CMX. (P<0. 05). 3) As for the clinical efficacy rate by standard criteria, proposed by the representative investigators committee of this study, clinical efficacy rate of CMX and CTM were 71.6% and 58.8% respectively, and the higher clinical efficacy rate of CMX than CTM was shown. 4) Assessment of clinical usefulness judged by the physicians in charge revealed the higher clinical usefulness of CMX than CTM. 5) Regarding the bacteriological effect, CMX showed the higher elimination rate of H. influenzae than CTM. (P<0. 1). 6) Improvement of the purulcncy of sputum and rale were significantly faster in CMX than CTM. (P<0.05). In the stratified group, consisting of the cases whose prior chemotherapies were ineffective, CMX showed significantly higher clinical efficacy rate than CTM. 7) The incidence of side effects and the abnormal change of laboratory findings were significantly less in CMX than CTM, and there was no severe adverse reaction in either medication. From the results of clinical response and side effects.it is considered that CMX clearly has a greater clinical usefulness than CTM in the treatment of chronic respiratory tract infections.

    Original languageEnglish
    Pages (from-to)613-636
    Number of pages24
    JournalChemotherapy
    Volume30
    Issue number6
    DOIs
    Publication statusPublished - 1982

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Clinical evaluation of cefmenoxime(sce-1365) in chronic respiratory tract infections'. Together they form a unique fingerprint.

    Cite this